The influence of prolactin (PRL) and melatonin on breast cancer represents a complex interplay of hormonal signaling with significant implications for tumor progression and therapeutic strategies. PRL, a polypeptide hormone produced primarily by the pituitary gland but also locally in mammary tissue, plays a dual role in breast physiology and pathology
1. It acts synergistically with estrogen and progesterone to promote proliferation and differentiation of mammary epithelial cells, processes that are essential for lactation
1,
2. However, its involvement in breast cancer remains debated, with most studies suggesting proliferative and pro-metastatic effects. PRL exerts its actions through specific transmembrane receptors (prolactin receptor [PRLR])
1,
2, activating signaling pathways such as JAK2/STAT5, Ras/MAPK, and PI3K/AKT, which drive cell survival, proliferation, and differentiation. Controversially, while PRL overexpression in cell culture enhances tumor growth, PRLR knockdown or antagonism can lead to more aggressive but less differentiated tumors, highlighting the context-dependent nature of PRL's role in breast cancer. Therefore, blood PRL concentration is important for the development of cancer
1-
4.